Retatrutide
LY3437943 · Triple G agonist
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Half-Life
~6 days
MW
Large peptide ~5200 Da
Amino Acids
N/A
Evidence
Moderate Evidence
Regulatory Status
Investigational. Phase III clinical trials. Not yet approved.
In Plain English
A triple hormone agonist hitting GLP-1, GIP, and glucagon receptors all at once — the most potent weight loss peptide in current clinical trials. Phase 2 data showed ~24% body weight reduction.
Overview
Retatrutide is a novel triple agonist of GIP, GLP-1, and glucagon receptors. Phase II trials showed mean weight loss of 24.2% at 48 weeks — significantly exceeding current approved agents. Phase III trials are underway.
Common Formats
- Injectable (weekly)
Storage Notes
Refrigerate.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Retatrutide.
Related Compounds
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.